SUPPRESSIVE MACROPHAGES, C-REACTIVE PROTEIN AND THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS AND IMMUNE THROMBOCYTOPENIC PURPURA
    252.
    发明公开
    SUPPRESSIVE MACROPHAGES, C-REACTIVE PROTEIN AND THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS AND IMMUNE THROMBOCYTOPENIC PURPURA 审中-公开
    抑制巨噬细胞,C反应蛋白和免疫治疗系统性红斑狼疮和血小板减少性紫癜

    公开(公告)号:EP2097087A4

    公开(公告)日:2013-01-02

    申请号:EP07867365

    申请日:2007-11-06

    Applicant: STC UNM

    CPC classification number: A61K35/15 A61K35/28 A61K38/1745 A61K2300/00

    Abstract: The present invention relates to the use of suppressive macrophage or dendritic cells (activated with C-reactive protein or CRP-related compounds), for the treatment of various disease states and conditions associated with immune thrombocytopenic purpura (ITP) and/or systemic lupus erythematosus (SLE), including lupus of the skin (discoid), systemic lupus of the joints, lungs and kidneys, hematological conditions including hemolytic anemia and low lymphocyte counts, lymphadenopathy and CNS effects, including memory loss, seizures and psychosis, among numerous others as otherwise disclosed herein. In another aspect of the invention, the reduction in the likelihood that a patient who is at risk for an outbreak of a disease state or condition associated with systemic lupus erythematosus or ITP will have an outbreak is an additional aspect of the present invention. In the case of ITP, methods of the present invention are used to increase platelet counts in the treated patient. In addition, in the case of ITP, the present invention relates to the use of CRP or a CRP-related compound in the absence of suppressive macrophages for the treatment of ITP.

    PLASMIDS AND METHODS FOR PEPTIDE DISPLAY AND AFFINITY-SELECTION ON VIRUS-LIKE PARTICLES OF RNA BACTERIOPHAGES

    公开(公告)号:CA2785992C

    公开(公告)日:2019-10-08

    申请号:CA2785992

    申请日:2010-12-31

    Applicant: STC UNM

    Abstract: The present invention relates to a system and method for controlling peptide display valency on virus-like particles (VLPs), especially including MS2 VLPs. In this method, large amounts of wild-type and low quantities of single-chain dimer coat proteins may be produced from a single RNA. Valency is controlled in immunogen (vaccine) production by providing a system that allows the production of large amounts of wild-type and low quantities of single-chain dimer coating proteins from a single RNA, allowing facile adjustment of display valency levels on VLPs, especially MS2 VLPS over a wide range, from few than one- on average- to as many as ninety per particle. This facilitates the production of immunogens and vaccines, including VLPs exhibiting low valency. Nucleic acid constructs useful in the expression of virus-like particles are disclosed, comprised of a coat polypeptide of MS2 modified by insertion of a heterologous peptide, wherein the heterologous peptide is displayed on the virus-like particle and encapsidates MS2 niRNA. Nucleic acid constructs are also disclosed which are useful in the expression of virus-like particles comprised of a coat polypeptide of PP7 modified by insertion of a heterologous peptide, wherein the heterologous peptide is displayed on the virus-like particle and encapsidates PP7 mRNA.

Patent Agency Ranking